Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study.

CONCLUSION: This nationwide study showed that standard chemotherapy with low-dose anthracycline is a risk factor for late-onset CHF in breast cancer survivors who were in their 50 s at breast cancer diagnosis. Long-term monitoring of late CHF should be considered in these younger breast cancer survivors. PMID: 32771950 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32771950?dopt=Abstract

Source: Breast - July 30, 2020 Category: Cancer & Oncology Authors: Chung IY, Lee JW, Moon HG, Shin KH, Han W, Son BH, Ahn SH, Noh DY Tags: Breast Source Type: research